| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CD-1530 | CTRPv2 | pan-cancer | AAC | -0.0031 | 0.9 |
| mRNA | Bortezomib | FIMM | pan-cancer | AAC | -0.012 | 0.9 |
| mRNA | Erlotinib | FIMM | pan-cancer | AAC | -0.013 | 0.9 |
| mRNA | UNC0638 | GDSC1000 | pan-cancer | AAC | -0.0021 | 0.9 |
| mRNA | ML050 | CTRPv2 | pan-cancer | AAC | 0.0027 | 0.9 |
| mRNA | BRD-K51490254 | CTRPv2 | pan-cancer | AAC | 0.0027 | 0.9 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | -0.0026 | 0.9 |
| mRNA | 5-FU | CTRPv2 | pan-cancer | AAC | 0.0023 | 0.9 |
| mRNA | WAY-362450 | CTRPv2 | pan-cancer | AAC | -0.0025 | 0.9 |
| mRNA | CAL-101 | CTRPv2 | pan-cancer | AAC | -0.0024 | 0.9 |